Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: SA53-OS (phase 2)Drug: SA53-OS (phase 1)
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Lamassu Bio Inc
- Target Recruit Count
- 70
- Registration Number
- NCT06578624
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath